Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Serum Institue of India

Reimagining Healthcare Using Mobile Health Technologies

Kim Shah, CEO of KnowYourMeds, explores digital health, AI, telemedicine, health literacy, and how to ensure a safe return to work amidst the ongoing COVID-19 pandemic. We also dive into...

Impetus Digital

- PMLiVE

Moderna launches COVID-19 vaccine booster study to address new variants

First participants receive company’s modified vaccine candidates

- PMLiVE

GSK, Vir seek EUA after scoring positive results for COVID-19 antibody VIR-7831

VIR-7831 reduced the risk of hospitalisation/death by 85% in high-risk COVID-19 patients

- PMLiVE

EMA starts rolling review of Lilly’s COVID-19 antibodies

CHMP will review the combination of bamlanivimab and etesemivab as well as bamlanivimab monotherapy

- PMLiVE

Stakeholder meeting kick-starts dialogue on COVID-19 vaccine supply chain issues

Meeting discussed potential solutions to COVID-19 vaccine manufacturing bottlenecks

- PMLiVE

Pfizer/BioNTech could supply three billion doses of COVID-19 vaccine in 2022

J&J reportedly facing vaccine supply issues in the EU

- PMLiVE

Pfizer/BioNTech’s COVID-19 vaccine neutralises Brazil variant, suggests study

Neutralisation of variant 'roughly equivalent' to original SARS-CoV-2 strain

- PMLiVE

EMA recommends use of Lilly’s COVID-19 antibody cocktail

Agency concludes bamlanivimab and etesevimab can be used to treat certain COVID-19 patients

- PMLiVE

Merck & Co, Ridgeback Biotherapeutics’ COVID-19 drug shows early promise

Molnupiravir led to a faster decrease in infectious virus among participants with early COVID-19

- PMLiVE

Germany backs use of AZ/Oxford COVID-19 vaccine in over-65s

Country's Health Ministry also recommended extending gap between doses to 12 weeks

- PMLiVE

GSK, Vir halt enrolment of phase 3 COVID-19 antibody study

Move comes after recommendation from independent data and safety monitoring board

- PMLiVE

CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate

Novartis will aid manufacturing for up to 50 million doses of CureVac's vaccine in 2021

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links